Arrowhead Research Corporation Subsidiary, Insert Therapeutics Inc., Publishes Interim Phase I Data from Human Clinical Trials for New Cancer Drug

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research Corporation (Nasdaq:ARWR) announced today that interim Phase I data has been published in the 2007 American Society for Clinical Oncology Proceedings (ASCO) (Abstract ID 32638). The data are from an ongoing Phase I clinical study designed to evaluate the safety, tolerability, and pharmacokinetics of its lead anti-cancer drug candidate, IT-101, in patients with inoperable or metastatic tumors. IT-101 is a conjugate of the potent anti-cancer drug camptothecin and Insert’s proprietary drug delivery technology, CyclosertTM.
MORE ON THIS TOPIC